JFJoshua Alexander Fein

Joshua Alexander Fein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joshua Alexander Fein has a total of 359 co-authors. Here are the top co-authors by number of shared publications:

  • Roni Shouval

    Memorial Sloan Kettering Cancer Center, New York, New York, United States

    21 shared publications
  • Arnon Nagler

    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, affiliated with Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    14 shared publications
  • Avichai Shimoni

    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, affiliated with Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    9 shared publications
  • Ronit Yerushalmi

    The Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, affiliated with Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    8 shared publications
  • Miguel-Angel Perales

    Memorial Sloan Kettering Cancer Center, New York, New York, United States

    7 shared publications
  • Ana Alarcon Tomas

    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA

    6 shared publications

Latest Publications

  • Real-World Assessment of Prophylactic Anakinra on Neurotoxicity and Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory B-Cell Lymphoma: An Inverse Probability of Treatment Weighting Analysis

    by Neela Easton, Mia Andreoli, Herman van Besien, Caitlin Gribbin, Michelle Pasciolla, Anna Alperovich, Mateo Mejia Saldarriaga, Barbara Ma, Nora Chokr, Amer Assal, et al.


  • Top Cited Papers
    Open Access

    An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma

    by Sandeep S. Raj, Teng Fei, Shalev Fried, Andrew Ip, Joshua A. Fein, Lori A. Leslie, Ana Alarcon Tomas, Doris Leithner, Jonathan U. Peled, Magdalena Corona, et al.

    Disease progression is a substantial challenge in patients with non-Hodgkin lymphoma (NHL) undergoing chimeric antigen receptor T cell (CAR-T) therapy. Here we present InflaMix (INFLAmmation MIXture Model), an unsupervised quantitative model integrating 14 pre-CAR-T infusion laboratory and cytokine measures capturing inflammation and end-organ function. Developed using a cohort of 149 patients with NHL, InflaMix revealed an inflammatory signature associated with a high risk of CAR-T treatment failure, including increased hazard of death or relapse (hazard ratio, 2.98; 95% confidence interval, 1.60–4.91; P < 0.001). Three independent cohorts comprising 688 patients with NHL from diverse treatment centers were used to validate our approach. InflaMix consistently and reproducibly identified patients with a higher likelihood of disease relapse and mortality, and it provided supplementary predictive value beyond established prognostic markers, including tumor burden. Moreover, InflaMix exhibited robust performance in cases with missing data, maintaining accuracy when considering only six readily available laboratory measures. These findings show that InflaMix is a valuable tool for point-of-care clinical decision-making in patients with NHL undergoing CAR-T therapy.


  • Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

    by Mohamed A. Kharfan-Dabaja, Razan Mohty, Neela Easwar, Patrick Johnston, Madiha Iqbal, Narendranath Epperla, Jean Yared, Nausheen Ahmed, Mehdi Hamadani, Amer Beitinjaneh, et al.

    Older patients with lymphoma are typically underrepresented in clinical trials with chimeric antigen receptor T cell (CAR T) therapy. In this multicenter, observational study we aimed to assess the safety and efficacy of standard CD19 CAR T in patients 80 years of age or older. At total of 88 patients, median age 82 (range, 80-89) years, were included. Diffuse large B cell lymphoma (DLBCL) (N = 60, 68.2%) represented the most common histology. Patients were treated mostly with axicabtagene ciloleucel (N = 41, 46.6%) followed by lisocabtagene maraleucel (N = 25, 28.4%). Cytokine release syndrome (CRS) (any grade) was seen in 68 (77.3%) and 51 (58%) developed immune effector cell-associated neurotoxicity syndrome (ICANS). Incidence of grade 3-4 CRS and ICANS were 7.4% and 31.4%, respectively. For patients with DLBCL/tFL, the 1-year NRM, relapse, PFS, and OS were 11.6%, 40.8%, 47.6%, and 61.2%, respectively. We conclude that CAR T is feasible and effective in patients 80 years or older with B cell lymphomas. These patients must be provided the opportunity to be evaluated for this curative approach.


  • A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation

    by Joshua A. Fein, Agnes McAuliffe, Kimberly Fischer, Owen Brady, Sean M. Devlin, Silvia Willumsen, Gonca Ozcan, Pat Montanaro, Yelena Pristyazhnyuk, Joseph DiGiuseppe, et al.

    Access to allogeneic and autologous hematopoietic stem cell transplantation (SCT) remains inadequate despite its curative potential across hematologic malignancies. In 2015, Hartford HealthCare (HHC) and the Memorial Sloan Kettering Cancer Center (MSK) established the Shared Care Model (SCM) with a primary aim of enhancing SCT access for HHC patients. The SCM comprises several components: an SCT-dedicated nurse-navigator, a health-information exchange for record sharing, telemedicine, and ongoing training of HHC clinicians in transplant patient selection and management. We evaluated the SCM's impact on SCT access across 126 patients with acute leukemia, myelodysplastic syndrome, and multiple myeloma from 2016-2020. The SCM facilitated 34 referrals. Socio-economic status of HHC referrals by Area Deprivation Index was significantly inferior (38 vs. 14, p < 0.001) when compared to 3,108 non-SCM referrals to MSK during the same period. Allogeneic recipients spent 68-247 days away from home, and autologous recipients 15-48, both requiring few subsequent visits to MSK.


  • Open Access

    Wild-Type p53 Overexpression in NPM1-Mutated AML: Potential Implications for Disease Biology and Therapy Response

    by Paul Barone, Siarhei Dzedzik, Ashley Kleinman, Christopher Chin, Cem Meydan, Itzel Valencia, Mayumi Sugita, Monica Guzman, Joshua Fein, Justin Kaner, et al.

    Somatic mutations in nucleophosmin (NPM1) are key in defining a common subtype of acute myeloid leukemia (NPM1-AML), characterized by chromosomal stability and favorable therapeutic responses. However, some patients exhibit a suboptimal response to initial treatment, and relapses are common, highlighting the need for novel biomarkers. Notably, NPM1and TP53 mutations rarely co-occur in AML, where TP53 mutations correlate with aneuploidy and poor survival outcomes. Here, we present transcriptomic and proteomic evidence of unexpectedly high wild-type (WT) TP53/p53 expression in a subset of NPM1-AMLs at baseline. Analyses of the Beat AML cohort indicate that NPM1-AMLs generally express more TP53than NPM1/TP53-WT AMLs. Among seventy-four NPM1-AML samples, those with the lowest TP53 co-expression are enriched for downregulated signatures linked to DNA repair, apoptosis, and the cell cycle. By profiling thirty-three primary patient samples using multiplex immunofluorescence staining with single cell-based quantitative digital image analysis, we observed increased p53 expression in NPM1-mutant cells compared to WT cells. Importantly, patients with primary refractory disease showed low p53 co-expression at diagnosis. These findings suggest that WT-p53 might play a crucial role in the biological and clinical characteristics seen in NPM1-AML.

  • Open Access

    Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

    by Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H. Mouhieddine, Juan Esteban Velez-Hernandez, Katherine Engles, Joshua A. Fein, Jorge Monge, Cara Rosenbaum, Roger Pearse, et al.

    B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay in the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion after infusion has been shown to inform depth and duration of response (DoR), but measuring this process remains investigational. This multicenter study describes the kinetics and prognostic impact of absolute lymphocyte count (ALC) in the first 15 days after CAR-T infusion in 156 patients with relapsed MM treated with the BCMA-targeting agents ciltacabtagene autoleucel and idecabtagene vicleucel. Patients with higher maximum ALC (ALCmax) had better depth of response, progression-free survival (PFS), and DoR. Patients with ALCmax >1.0 × 103/μL had a superior PFS (30.5 months vs 6 months; P < .001) compared with those with ≤1.0 × 103/μL, whereas patients with ALCmax ≤0.5 × 103/μL represent a high-risk group with early disease progression and short PFS (hazard ratio, 3.4; 95% confidence interval, 2-5.8; P < .001). In multivariate analysis, ALCmax >1.0 × 103/μL and nonparaskeletal extramedullary disease were the only independent predictors of PFS and DoR after accounting for international staging systemic staging, age, CAR-T product, high-risk cytogenetics, and the number of previous lines. Moreover, our flow cytometry data suggest that ALC is a surrogate for BCMA CAR-T expansion and can be used as an accessible prognostic marker. We report, to our knowledge, for the first time the association of ALC after BCMA CAR-T infusion with clinical outcomes and its utility in predicting response in patients with R/R MM.


  • Open Access

    Under AI’s lens: spotting mutations visually

    by Joshua A. Fein, Sanjay S. Patel

    In the 9 January 2024 issue of Blood Advances, Kockwelp et al1 presented an artificial intelligence (AI) system for predicting key genetic and cytogenetic In the 9 January 2024 issue of Blood Advances, Kockwelp et al1 presented an artificial intelligence (AI) system for predicting key genetic and cytogenetic


  • Open Access

    Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

    by Joshua A. Fein, Roni Shouval, Elizabeth Krieger, Stephen R. Spellman, Tao Wang, Henning Baldauf, Katharina Fleischhauer, Nicolaus Kröger, Mary Horowitz, Martin Maiers, et al.

    In acute myeloid leukemia (AML), donor natural killer cell killer immunoglobulin–like receptors (KIR) and recipient HLA interactions may contribute to the graft-versus-leukemia effect of allogeneic hematopoietic cell transplantation (HCT). Analyses of individual KIR/HLA interactions, however, have yielded conflicting findings, and their importance in the HLA-matched unrelated donor (MUD) setting remains controversial. We systematically studied outcomes of individual donor-KIR/recipient-HLA interactions for HCT outcomes and empirically evaluated prevalent KIR genotypes for clinical benefit. Adult patients with AML (n = 2025) who received HCT with MUD grafts in complete remission reported to the Center for International Blood and Marrow Transplantation were evaluated. Only the donor-2DL2+/recipient-HLA-C1+ pair was associated with reduced relapse (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.67-0.93; P = .006) compared with donor-2DL2–/recipient-HLA-C1+ pair. However, no association was found when comparing HLA-C groups among KIR-2DL2+–graft recipients. We identified 9 prevalent donor KIR genotypes in our cohort and screened them for association with relapse risk. Genotype 5 (G5) in all recipients and G3 in Bw4+ recipients were associated with decreased relapse risk (HR, 0.52; 95% CI, 0.35-0.78; P = .002; and HR, 0.32; 95% CI, 0.14-0.72; P = .006; respectively) and G2 (HR 1.63, 95% CI, 1.15-2.29; P = .005) with increased relapse risk in C1-homozygous recipients, compared with other patients with the same ligand. However, we could not validate these findings in an external data set of 796 AML transplants from the German transplantation registry. Neither a systematic evaluation of known HLA-KIR interactions nor an empiric assessment of prevalent KIR genotypes demonstrated clinically actionable associations; therefore, these data do not support these KIR-driven strategies for MUD selection in AML.


  • Fecal microbiota transplantation in capsules for the treatment of steroid refractory and steroid dependent acute graft vs. host disease: a pilot study

    by Ilan Youngster, Adi Eshel, Mika Geva, Ivetta Danylesko, Israel Henig, Tsila Zuckerman, Shalev Fried, Ronit Yerushalmi, Noga Shem-Tov, Joshua A. Fein, et al.

    Acute graft-versus-host disease (aGvHD) is a serious complication of allogeneic hematopoietic stem-cell transplantation with limited treatment options. The gut microbiome plays a critical role in aGvHD pathogenesis. Fecal microbiota transplantation (FMT) has emerged as a potential therapeutic approach to restore gut microbial diversity. In this prospective pilot study, 21 patients with steroid-resistant or steroid-dependent lower gastrointestinal aGvHD received FMT in capsule form. At 28 days after the first FMT, the overall response rate was 52.4%, with 23.8% complete and 28.6% partial responses. However, sustained responses were infrequent, with only one patient remaining aGvHD-free long-term. FMT was generally well-tolerated. Microbiome analysis revealed dysbiosis in pre-FMT patient stool samples, with distinct microbial characteristics compared to donors. Following FMT, there was an increase in beneficial Clostridiales and a decrease in pathogenic Enterobacteriales. These findings highlight the potential of FMT as a treatment option for steroid-resistant aGvHD. Trial registration number NCT #03214289.


  • Open Access

    From Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T- Cell Therapy: Less Is Better

    by Giovanna Melica, Alejandro Luna De Abia, Magdalena Corona, Joshua Fein, Parastoo B Dahi, Sergio A. Giralt, Ivan Landego, Richard J. Lin, Maria Lia Palomba, Allison Parascondola, et al.

    Disclosures. Melica:Pfizer: Honoraria, Research Funding; Janssen: Honoraria; Gilead: Honoraria, Research Funding. Giralt:Amgen, Actinuum, Celgene/BMS, Omeros, J